Enterovirus D68
| Morphology | Positive-sense single-stranded RNA virus. | 
|---|---|
| Disease | Enterovirus D68 (EV-D68) is a specific type of non-polio enterovirus. It was first
                                                identified in California in 1962 but since then was only rarely reported in the United
                                                States compared to other non-polio enteroviruses. In the fall of 2014, EV-D68 was
                                                associated with a nationwide outbreak of severe respiratory illness in the United
                                                States and Canada. In some patients, EV-D68-associated illness was severe enough to
                                                require intensive care unit (ICU) admission. | 
| Zoonosis | unknown | 
| Host Range | Humans | 
|---|---|
| Modes of Transmission | Direct contact with infected secretions or mucous membranes. | 
| Signs and Symptoms | Respiratory illness: Mild symptoms may include runny nose, sneezing, cough and body
                                                         and muscle aches. Severe symptoms may include wheezing and difficulty breathing. | 
| Infectious Dose | unknown | 
| Incubation Period | 3 to 6 days. | 
| Prophylaxis | None available. | 
|---|---|
| Vaccines | None available. | 
| Treatment | No specific treatment for people with respiratory illness. | 
| Surveillance | Monitor for symptoms. | 
| MSU Requirements | Report any exposures. | 
| Laboratory Acquired Infections (LAIs) | none | 
|---|---|
| Sources | Virus is shed from saliva. Cultures, frozen stocks, other samples described in IBC
                                                            protocol. | 
| CDC: | https://www.cdc.gov/non-polio-enterovirus/about/about-enterovirus-d68.html?CDC_AAref_Val=https://www.cdc.gov/non-polio-enterovirus/about/ev-d68.html | 
|---|---|
| BMBL: | https://www.cdc.gov/labs/BMBL.html | 
| NIH Guidelines: | 
| Risk Group 2 | Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available. | 
|---|---|
| BSL2 | For all procedures involving suspected or known infectious specimen or cultures. | 
| ABSL2 | For all procedures utilizing infected animals. | 
| Small | Notify others working in the lab. Remove PPE and don new PPE. Cover area of the spill
                                                with absorbent material and add fresh 1:10 bleach:water. Allow 20 munutes (or as directed)
                                                of contact time. After 20 minutes, cleanup and dispose of materials. | 
|---|---|
| Large | 
 | 
| Mucous membrane  | Flush eyes, mouth, or nose for 5 minutes at eyewash station. | 
|---|---|
| Other Exposures  | Wash area with soap and water for 5 minutes.  | 
| Reporting | Immediately report incident to supervisor, complete a First Report of Injury form, and submit to Safety and Risk Management. | 
| Medical Follow-up  | During business hours: Bridger Occupational Health 3406 Laramie Drive. Weekdays 8am -6pm.  Weekends 9am-5pm After business hours: Bozeman Deaconess Hospital Emergency Room 915 Highland Blvd Bozeman, MT | 
| Disinfection | Susceptible to 1:10 bleach:water, 70 % ethanol, accelerated hydrogen peroxide | 
|---|---|
| Inactivation | Inactivated by moist heat (1 hour at 121oC) and dry heat (1 hour at 160-170 C). | 
| Survival Outside Host | unknown | 
| Minimum PPE Requirements | Lab coat, disposable gloves, safety glasses, closed toed shoes, long pants | 
|---|---|
| Additional Precautions | Additioanl PPE may be required depending on lab specific SOPs and IBC Protocol. | 
